ABSTRACT
Objective: ANRIL is an important antisense noncoding RNA gene in the INK4 locus [9p21.3], a hot spot region associated with multiple disorders including coronary artery disease [CAD], type 2 diabetes mellitus [T2DM] and many different types of cancer. It has been shown that its expression is dysregulated in a variety of immune-mediated diseases. CAD is a major problem in T2DM patients and the cause of almost 60% of deaths in these patients worldwide. The aim of the present study was to compare the expression level of ANRIL between T2DM patients with and without CAD
Materials and Methods: In this case-control study, we examined ANRIL expression in peripheral blood mononuclear cell samples by quantitative reverse transcriptionpolymerase chain reaction [RT-qPCR] in 64 T2DM patients with and without CAD [33 CAD+ and 31 CADpatients respectively, established by coronary angiography]
Results: Expression analysis revealed that ANRIL was up regulated [2.34-Fold, P=0.012] in CAD+ versus CAD diabetic patients. Data from receiver operating characteristic [ROC] curve analysis has shown that ANRIL could act as a potential biomarker for detecting CAD in diabetic patients
Conclusion: The expression level of ANRIL is associated with presence of CAD in diabetic patients and could be considered as a potential peripheral biomarker